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Objectives: To perform a systematic review of the methods used for background 
parenchymal enhancement (BPE) evaluation on breast magnetic resonance imaging 
(MRI).  
Methods: Studies dealing with BPE assessment on breast MRI were retrieved from major 
medical libraries independently by four reviewers up to 6 October 2015. The keywords 
used for database searching are “background parenchymal enhancement’, ‘parenchymal 
enhancement’, “MRI” and “breast”. The studies were included if a qualitative and/or 
quantitative methods for BPE assessment were described.  
Results: Of the 420 studies identified, a total of 52 articles were included in the systematic 
review. N=28 studies performed only a qualitative assessment of BPE, N=13 studies 
performed only a quantitative assessment and N=11 studies performed both qualitative 
and quantitative assessment. A wide heterogeneity was found in the MRI sequences and 
in the quantitative methods used for BPE assessment.    
Conclusions: Wide variability exists in quantitative evaluation of BPE on breast MRI. 
More studies focused on a reliable and comparable method for quantitative BPE 
assessment are needed.  























































































As stated by the research committee of the European Society of Radiology (ESR), the 
future of medicine lies in the so-called ‘personalised medicine’ (PM) [1,2]. The concept of 
PM could be reassumed in delivering the right treatment to the right patient at the right 
time. The concept of personalized medicine is strictly linked to the “precision medicine” 
that has been defined in 2011 by the National Research Council of the National 
Academies white paper entitled “Toward Precision Medicine: Building a Knowledge 
Network for Biomedical Research and a new Taxonomy of Disease” [3]. On the light of 
these new goals of modern medicine, biomedical imaging requires a correct and rational 
use of quantitative imaging biomarkers (QIBs) [4]. 
In addition, implementation of quantitative imaging on a large scale will be critical to meet 
the demands of PM [4]. Indeed, PM presents new challenges to the radiologists with the 
need of validation and assessment of QIBs for diagnosis and treatment response 
assessment [1-6]. One primary metrology area of interest in the assessment of 
performance of a quantitative imaging biomarker is the ability of the QIB to consistently 
reproduce equivalent results when conditions change, as would be expected in any clinical 
trial [6]. In this perspective, background parenchymal enhancement (BPE), the term used 
to describe the enhancement of the normal breast tissue, is emerging as imaging 
biomarker [7]. 
The ‘degree’ of BPE is linked to the risk of developing breast cancer, may affect reading 
breast MRI, the staging and the risk of cancer even long-term outcome, particularly in 
patients with certain subtypes at immunohistochemistry [8-15]. BPE can be visually 
assessed qualitatively using the BI-RADS scores or quantitatively using software [7,16]. 
However, radiologists’ agreement for BPE qualitative evaluation is fair [17] and, to the best 
of our knowledge, there is a lack of uniformity on quantitative measurements of 














































































method based on percentage is not supported by the American College of Radiology 
(ACR), suggesting the need of further research in this topic [16]. It is crucial that, in the era 
of PM, the methods used for evaluation of background parenchymal enhancement, as for 
others imaging biomarkers, are reliable and comparable among different imaging sites [5]. 
Therefore, the purpose of this study is to perform a systematic review of the methods 

















































































We followed the guidelines defined by the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) [18]. The protocol of this study was published on 
PROSPERO (International Prospective Register of Systematic Reviews; protocol number: 
CRD42015026904) on 8 October 2015 (http://www.crd.york.ac.uk/PROSPERO/). 
Search strategy 
We identified all relevant studies that assessed the evaluation of background parenchymal 
enhancement (BPE) on breast MRI. A literature search using PUBMED (http://www.
pubmed.org), Embase (http://www.embase.com.proxy.medlib.iupui.edu/search), ISI Web 
of Science (http://apps.webofknowledge.com), SpringerLink, ScienceDirect and Cochrane 
library (http://www.thecochranelibrary.com) was performed independently by four 
reviewers (Blind, Blind, Blind, Blind) up to 6 October 2015. Manual revision of the 
reference lists was also performed to integrate the initial search with additional studies, if 
necessary. We did not contact directly authors for additional data. 
The search strategy included the following terms related to studies on humans: 
‘background parenchymal enhancement’ or ‘parenchymal enhancement’, in combination 
with ’magnetic resonance imaging’, ‘evaluation’ or ‘assessment’, and ‘breast’.  
The detailed search strategy in PubMed is presented in Supplemental Appendix S1. 
Inclusion criteria 
Studies were included if they met all the following criteria: 
1. Women older than 18 years who performed breast MRI  
2. Background parenchymal enhancement assessed on MRI 
3. The method used for background parenchymal enhancement assessment clearly 
stated: qualitative with BI-RADS, qualitative without BI-RADS, automated quantitative on 
2D MRI slices, automated quantitative on 3D MRI volumes, semi-automated quantitative 














































































4. Languages: only publications in English were included. 
Exclusion criteria: (1) case reports or case series, review articles, letters, comments; (2) 
duplicate publication; (3) BPE not assessed; (4) MRI exams below 1.5T.  
No publication date restriction was used. 
Study selection 
Two authors (Blind, Blind) independently and manually reviewed article titles and abstracts 
for study selection, based on the pre-defined criteria. Then, the same authors 
independently read the methods of the full text of those studies to confirm fulfilment of the 
inclusion criteria. Disagreements arising during each phase of the study selection were 
resolved in consensus. If consensus could not be reached, a clinical expert (Blind) was 
asked to resolve any disagreements.  
Data extraction and analysis 
Two authors (Blind, Blind) independently extracted the data from each eligible study. A 
duplicate data extraction was performed and discrepancies were resolved by consensus. 
The following data were extracted from each study: first author, journal and publication 
year, country of the study, study designation (retrospective or prospective), study 
population, magnetic field of MRI scanner (1.5 T or 3.0 T), menstrual period of patients 
undergoing MRI, the type of contrast media used (high relaxivity and not high relaxivity 
contrast media) the type of BPE assessment (qualitative method, quantitative method, 
including automated software), the sequences which BPE was qualitatively and 
quantitatively assessed and the method used for quantitative evaluation of BPE. In 
particular, we recorded studies assessing BPE quantitatively using region-of-interest 
(ROI), fibroglandular tissue segmentation, automatic method or other methods. To assess 
studies using ROI, we considered studies in which BPE was assessed by using a region of 
interest traced to include normal fibroglandular tissue, or the most enhancing part of the 














































































excluding breast lesion enhancement. To assess studies using fibroglandular tissue 
segmentation, we considered studies in which BPE was calculated by the enhancements 
of every pixels/voxel contained within a previously segmented fibroglandular tissue. To 
assess studies using an automatic method, we considered studies in which was specified 
the use of a fully automatic software that gives the value of BPE without the need of 
further control by a radiologist. We also recorded studies using other methods, different 
from the ROI, fibroglandular or automatic one.  
Among studies assessing BPE qualitatively, we recorded each study with intra and 
interreader agreement assessment for all readings by using the kappa statistics. We 
recorded kappa values for both ordinal (minimal, mild, moderate or marked BPE) and 
dichotomized variables (low and high BPE), when assessed. Strength of kappa agreement 
was defined as follows: 0.00–0.20, slight; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.81, 
substantial; 0.81–1.00, almost perfect. 
We divided articles in those published in 2015 and those published before 2015 to 
evaluate the increase interest on this topic in the last year. We performed a narrative 
synthesis of the qualitative and quantitative methods reported.  
Risk of bias 
The quality assessments of the eligible study were evaluated independently by two 
authors (Blind, Blind) using a modified Quality Assessment of Studies of Diagnostic 
Accuracy Studies (QUADAS-2) checklist, which comprised four domains: patient selection, 
index test and reference standard, and flow and timing. For the purpose of this study, the 
domains “index test” and “reference standard” were considered together:  in addition to the 
standard questions of these domains, we included the quality of the description of BPE 
assessment and the quality of MR images where the BPE assessment was performed, 
when available. Each domain is assessed in terms of risk of bias and the first three in 














































































the standard questions of each domain represent the judgment regarding bias and 
applicability: low risk of bias, high risk of bias and insufficient data to permit a judgement, 
respectively. The two authors then discussed the results of their quality assessments. 


















































































The initial database searching identified 420 articles. A total of 63 full-text articles were 
assessed after removal of duplicates and reading abstracts because they did not meet 
selection criteria. From the 63 full-text articles, 11 studies were excluded because they did 
not meet screening criteria and a total of 52 articles were included in the systematic review 
(Figure 1). Table 1 and Table 2 show characteristics of the included studies that 
assessed BPE with a qualitative and quantitative method, respectively. Among these 52 
studies, 28 studies (54%) performed only a qualitative assessment, 13 studies (25%) 
performed only a quantitative assessment and 11 studies (21%) performed both qualitative 
and quantitative assessment of BPE and were included in both tables. Among these 52 
studies, 20 studies (38%) were published in 2015. 
Qualitative BPE assessment 
Among the 39 (28+11) studies that assessed BPE qualitatively [7,8,10-13,15,17,19-49], 
38% (15/39) were published during 2015 (January-October) and 62% (24/39) were 
published during 2010-2014. Most of the studies were performed in the United States of 
America (17/39) and Republic of Korea (10/39) and Japan (6/39). Only one study [49] had 
a prospective study design. The patient population of the included studies ranged from 18 
to 1275 numbers of patients. N=20 studies performed breast MRI using a 1.5 T scanner, 
nine studies performed breast MRI using a 3.0 T scanner and nine studies using both 1.5 
T and 3.0 T scanners. In one studies [11] the MRI scanner was not clearly stated but it 
was above 1.5T. Most of the studies (59%; 23/39) used gadopentetate dimeglumine as 
contrast agent. Only three studies (8%; 3/39) used high-relaxivity contrast agent [7,34,47]. 
All the studies graded BPE on a four-point scale as minimal, mild, moderate, or marked in 
accordance with the Breast Imaging-Reporting and Data System (BI-RADS) categories 
[16]. Iacconi et al. [25] classified BPE according to BI-RADS lexicon but for statistical 














































































BPE using a combination of unenhanced and contrast-enhanced fat-suppressed T1-
weighted and subtracted images, and five studies added also maximum-intensity 
projection images; N=14 studies qualitatively assessed BPE using a combination of post-
contrast fat-suppressed T1-weighted and/or subtraction images; one studies [27] used 
only maximum-intensity-projection images; in three studies the sequences used for 
qualitative BPE assessment were not clearly stated (Table 1).  
A total of nine studies performed intra and/or interreader agreement of qualitative 
evaluation of BPE [7,8,17,22,31,36,37,39,48]. In particular, four studies [7,8,17,39] 
evaluated both intra and interreader agreement and the other five studies evaluated only 
interreader agreement. Kappa values for intrareader agreement were moderate to almost 
perfect, while more variability was found for kappa values for interreader agreement, that 
was demonstrated to be fair to almost perfect (Table 3).  
In the majority of studies (7 of 9) the agreement was assessed for ordinal variables. In 
studies by King et al. [8] and by Melsaether et al. [17] authors assessed intra and 
interreader agreement for both ordinal and dichotomized variables, but the strength of 
kappa agreement was not changed (kappa values for intrareader agreement were 
substantial and for interreader agreement were moderate in both studies).  
Quantitative BPE assessment 
Among the 24 (13+11) studies that assessed BPE quantitatively [7,14,40-62], 33% (8/24) 
were published during 2015 (January-October) and 67% (16/24) were published during 
2008-2014. Most of the studies were performed in the United States of America (9/24) and 
Republic of Korea (4/24) and Germany (4/24). A total of seven studies were prospective, 
and 17 studies were retrospective. The patient population of the included studies ranged 
from 16 to 651 numbers of patients. N=18 studies performed breast MRI using a 1.5 T 
scanner and five studies performed breast MRI using a 3.0 T scanner. Most of the studies 














































































studies (8%; 2/24) [7,47] used a high-relaxivity contrast agent (gadobenate dimeglumine, 
MultiHance). N=15 studies (62%) performed a quantitative evaluation of parenchymal 
enhancement from a ROI. Among these studies, BPE was described as a signal 
enhancement ratio in four studies [43,46,47,52]. The signal enhancement ratio was based 
on comparison of signal intensity in an early contrast-enhanced image with signal intensity 
in a delayed contrast-enhanced image relative to a pre-contrast image.  
BPE was described as a percentage enhancement rates or relative percentage 
enhancement in eleven studies [41,42,44,45,48,49,53-55,58,59], with the use of both pre- 
and post-contrast images. There was a wide heterogeneity on time selection of images 
obtained after contrast agent injection for relative percentage enhancement or percentage 
enhancement rates calculation.  
Three studies performed a quantitative evaluation of BPE using an automatic method 
[7,57,61]. Tagliafico et al. [7] assessed BPE using fully automated software that performed 
an objective and reproducible voxel-by-voxel analysis. This software used an algorithm 
based on the maximum entropy method and a threshold value [7]. Mazurowski et al. [57] 
used computer vision algorithms that extracted all the features automatically, including 
dynamic feature of the background parenchyma [57]. Wu et al. [61] used a validated fully 
automated method that allowed segmentation and quantitatively measure of fibroglandular 
tissue and BPE [61].  
Qualitative and quantitative BPE assessment 
Among the 11 studies that assessed BPE both in a qualitative and quantitative methods 
[7,40-49], 27% (3/11) were published during 2015 (January-October) and 73% (8/11) were 
published during 2010-2014. Most of the studies were performed in the United States of 
America (3/11) and Republic of Korea (3/11). The majority of the studies (10/11) were 
prospective. The patient population of the included studies ranged from 26 to 229 numbers 














































































performed breast MRI using a 3.0 T scanner. Most of the studies (45%; 5/11) used 
gadopentetate dimeglumine (Magnevist) as contrast agent. Among these 11 studies that 
assessed BPE both in a qualitative and quantitative methods, only the study of Kim MY et 
al. [46] found a statistical difference between qualitative and quantitative data. 
Considering menstrual period of pre-menopausal patients that underwent MRI, in the 
majority of studies (30 of 52) the patient menstrual cycle was unknown or not available 
[8,10,12,13,15,20,21,23,25,27,28,30,32-35,38,39,45,46,47,50-54,57,59,60,62]. In five 
studies [11,17,19, 36,43], authors acknowledged that, due to the retrospective nature of 
the study, it was not possible to analyse the point of menstrual cycle, although, following 
Institutional protocol, screening breast MRI of pre-menopausal patients are performed 
during the second week of the menstrual cycle. In a total of 14 studies authors stated the 
menstrual period [7,22,24,26,31,37,40-42, 44,48,55,56,61]. In eight of these 14 studies, 
breast MRI were performed ideally in the second week of the menstrual cycle 
[7,22,24,37,41,42,56,61]. In three studies [29,49,58], the patients were post-menopausal 
women.  
Risk of Bias 
Assessment of the methodological quality of the included studies by the modified 
QUADAS-2 tool is depicted in Table 4 and Table 5. 
The domain of “patient selection” for the qualitative and quantitative BPE evaluation was 
unclear in the studies of DeMartini et al. [11], Choi et al. [21], Jansen et al. [43], Kajihara et 
al. [44], Kang et al. [55], Kim JY et al. [45], Park et al. [35]. The domain “index test and 
reference standard” was described in detailed in most of the studies that assessed BPE 
qualitatively and quantitatively. High risk of bias and concerns regarding applicability were 
judged in the paper of Chen et al. [50] and in the papers of Grimm et al. [23] and Myers et 
al. [34], specifically for low quality of MR imaging examinations where the BPE 














































































respectively. The domain of ‘flow and timing’ was the only domain to potentially contribute 
a high risk of bias in the papers evaluated. However, we believe that this domain could be 
less relevant because we focused only on the methods of assessment of BPE that in most 



















































































We performed a systematic review of the literature currently available about qualitative and 
quantitative assessment of BPE in breast MRI. We divided the 52 articles included in the 
systematic review in those that performed a qualitative evaluation of BPE and in those that 
performed a quantitative evaluation of BPE. Most of the studies found (28/52) performed 
only a qualitative evaluation of BPE, 13 studies performed only a quantitative evaluation 
and 11 studies both qualitative and quantitative evaluation of BPE. Therefore, a total of 24 
studies performed a quantitative assessment of BPE. Among these 24 studies, one of the 
most difficult issues was the analysis of the quantitative method used, due to the lack of 
standardization of the BPE quantitative assessment. Indeed, the studies used different 
methods and software to evaluate BPE, although the majority of these studies performed a 
quantitative evaluation of parenchymal enhancement from a region-of-interest (ROI). 
However, the use of ROI usually needs radiologist involvement, and this issue should be 
faced in the perspective of a standardized quantitative imaging evaluation of BPE. In 
addition, only three studies used an automatic method, and in all these studies different 
software were used. We can state that in the “era” of PM and emerging QIBs, BPE 
quantitative assessment is still far to be standardized. The ACR distances itself from 
prescribing an absolute quantification method for BPE assessment [16], and this is 
probably the source of the heterogeneity that we found in our study. Indeed, our study 
found extensive heterogeneity in the methods used for BPE quantitative assessment and 
encourage further studies assessing comparable method for quantitative BPE evaluation.  
Among the 11 studies that performed a BPE assessment with both qualitative and 
quantitative methods, only one study [46] reported a statistical difference between the 
qualitative and quantitative methods used. Noteworthy, the study by Kim et al. [45] was 
able to associate high values of BPE around the tumours on the pre-operative MRI with an 














































































approach, this information would have been missed. Indeed, with a study design similar to 
that of Kim et al., [46] a huge number of breast MRI examinations were necessary to 
obtain the same information.  
Our systematic review found that the majority of papers published had a retrospective 
design, and only few studies were prospective. A retrospective study design reduces the 
possibility of associating BPE with others factors relevant to tumour biology. In addition, in 
the majority of the studies the menstrual period of pre-menopausal women that underwent 
MRI was unknown or not available.  
Regarding the contrast media used, we found that only few studies used high-relaxivity 
contrast media. The use of a high relaxivity contrast media such as gadobenate 
dimeglumine is reported to offer advantages for lesion conspicuity, detection rate, and 
sensitivity for malignant breast lesions [63]. Besides, a higher enhancement of benign 
lesions and breast parenchyma is possible with a high relaxivity contrast media [63]; 
therefore, we cannot confirm that the amount of BPE assessed with the same method, but 
different contrast media, is comparable.  
Regarding the quality assessment, we used a modified QUADAS-2 checklist, since our 
systematic review did not focus on diagnostic accuracy studies; indeed, we merged the 
domain “index test” and “reference standard”. In addition to the standard questions of 
these domains [64], we also considered the quality of the description of BPE assessment 
and the quality of MR images where the BPE assessment was performed. In spite of the 
modified method for quality assessment, the domain of ‘flow and timing’ was the only 
domain to potentially contribute a high risk of bias in the included studies. However, this 
review focused on the methods used on BPE evaluation, and the majority of the studies 
performed the assessment with a retrospective review of the breast MRI dataset; 
therefore, we believe that this domain could be less relevant and the overall risk of bias in 














































































Considering qualitative evaluation, BPE was always graded on a four-point scale by the 
BI-RADS categories representing the main standardized area in BPE assessment, as 
recommended by the ACR BI-RADS fifth edition itself [16]. However, a huge variability in 
the MRI sequences adopted to assess BPE was noted, although the main principle was to 
find the sequences where the amount of BPE was most evident. It is clear that there is no 
consensus on what MRI sequences the BPE should be assessed even with the relatively 
simple suggested BI-RADS grading system. In addition, a wide variability was found 
among kappa values for the interreader agreement, from fair to almost perfect agreement. 
Considering intrareader agreement, kappa values were moderate to almost perfect. 
However only 9 of 39 studies assessed intra and/or interreader agreement for qualitative 
evaluation of BPE, and further studies could be useful on this topic. 
Considering quantitative evaluation, we acknowledge that our study did not include a 
detailed descriptions of the methods used for quantitative assessment of BPE. However, 
we performed the division of these studies among four main different methods (ROI, 
fibroglandular tissue segmentation, automatic methods or other methods) to allow a more 
uniform analysis. Further systematic reviews that focus on this topic could be useful to 
provide future directions for a standardization of quantitative methods used to assess 
BPE.  
Finally, the first study about BPE assessment was published in 2008 [52] and the 38% 
(20/52) of all the studies included were published during 2015, reflecting the growing 
interest in this topic. The relatively recent interest in the BPE assessment could be another 
possible explanation for the wide variability found in the sequences used for the qualitative 
assessment and in the methods used for the quantitative assessment. 
In conclusion, since background parenchymal enhancement (BPE) is considered an 
emerging imaging biomarker, new methods to assess BPE quantitatively are being 














































































quantitative evaluation of BPE on breast MRI. In addition, no consensus exists on the 
sequences to be used to visually assess BPE. Therefore, more studies on quantitative 
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Table 1: Characteristic of the 39 studies that assess BPE qualitatively included in the 
systematic review.  
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Articles with both qualitative and quantitative assessment of BPE; °early post-contrast images were used; ⌃the unenhanced images 


















































































Table 2: Characteristic of the 24 studies that assess BPE quantitatively included in the 
systematic review. In the last column there is the name of the software used, when 
retrievable.  
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Articles with both qualitative and quantitative assessment of BPE;  MR images; R: retrospective study; P: prospective study. 
*Automatic method.  
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Table 3: Intra- and interreader agreement for all readings for qualitative BPE evaluation 
among the nine studies that assessed agreement by using kappa statistics.  
In two studies (King et al. and Melsaether et al.) authors assessed the agreement also for 















DeLeo et al.[22] 2015 AJR 2 n.a. 0.49 
King et al.[31] 2012 Eur Radiol 2 n.a. 0.95 
King et al.[8] 2011 Radiology 2 0.62(0.69) 0.47(0.57) 
Melsaether et al.⌃[17] 2014 AJR 4 0.79(0.80) 0.45(0.47) 
Preibsh et al.  2015 Eur Radiol 2 n.a. Right breast:0.73 
Left breast:0.77 
Price et al.[37] 2014 Eur Radiol 3 n.a. 0.3-0.6 
Scaranelo et al.[48] 2013 Radiology 2 n.a. 0.37 
Tagliafico et al.[7] 2015 BJR 2 0.69 0.70 
Yoon et al.[39] 2015 Eur Radiol 2 0.82 0.85 
⌃pooled over all four readers; values after training at the end of the third lecture. 
kappa values before neoadjuvant chemotherapy. 















































































Table 3: Risk of bias table demonstrating overall risk of bias for each of the 
domains of patient selection, index test and reference standard, flow and timing. 




Index Test and 
Reference Standard  
Flow and 
Timing 
Albert et al. + + + 
Amarosa et al.  + + ? 
Baek et al.  + + + 
Cho et al.  + + + 
Choi et al.  ? + ? 
Cubuk R et al.  + ? ? 
DeMartini et al. ? + + 
DeLeo et al. + + + 
Dontchos et al.  + + + 
Grimm et al.  + - ? 
Hambly et al. + + - 
Hansen et al. + + + 
Iacconi et al. + + ? 
Jansen et al. ? + ? 
Kajihara et al. ? + ? 
Kawamura et al. + + + 
Kim JY et al. ? + + 
Kim MY et al. + ? + 














































































Kim SA et al. + + + 
Kim YJ et al. + ? - 
King et al. + + + 
King et al. + + + 
King et al. + + + 
King et al. + + + 
Kohara et al. + + ? 
Koo et al. + + + 
Melsaether et al. + + + 
Myers et al. + - ? 
Park et al.  ? + ? 
Preibsh et al. + + ? 
Price et al. + + + 
Scaranelo et al.  + + + 
Schrading et al. + + + 
Tagliafico et al.  + + + 
Uematsu et al.  + + ? 
Uematsu et al. + + ? 
Uematsu et al. + + ? 
Yoon et al.  + + ? 















































































Table 4: Risk of bias table demonstrating overall risk of bias for each of the 
domains of patient selection, index test and reference standard, flow and timing. 




Index Test and 
Reference Standard  
Flow and Timing 
Amarosa et al.  + + ? 
Chen et al.  + - ? 
Chen et al.  + + ? 
Cho et al.  + + + 
Cubuk R et al.  + ? - 
Hattangadi et al. + ? ? 
Hegenscheid  et al. + + + 
Hegenscheid  et al. + + + 
Jansen et al.  + + ? 
Kajihara et al.  ? + ? 
Kang et al. ? + + 
Kim JY et al.  ? + + 
Kim MY et al. + ? ? 
Kim SA et al. + + + 
Klifa et al.  + + + 
Mazuroski et al. + ? ? 
Mousa et al.  + + - 
Scaranelo et al.  + + + 
Schrading et al. + + + 
Schrading et al. + ? + 














































































Van der Velden et al. + + + 
Wu et al. + + + 
Yang et al. + + ? 
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